

Clerk of the House of Representatives  
Legislative Resource Center  
B-106 Cannon Building  
Washington, DC 20515

Secretary of the Senate  
Office of Public Records  
232 Hart Building  
Washington, DC 20510

RECEIVED  
SECRETARY OF THE SENATE

02 AUG 13 PM 2:31

# LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name <b>Clark &amp; Weinstock</b>			
2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address <b>1775 I Street NW, Ste 700</b> City <b>Washington,</b> State/Zip (or Country) <b>DC 20006</b>			
3. Principal Place of Business (if different from line 2) City <b>New York,</b> State/Zip (or Country) <b>NY 10017</b>			
4. Contact Name <b>Lisa Hayes</b>	Telephone <b>202-261-4025</b>	E-mail (optional) <b>lisa@cwdc.com</b>	5. Senate ID # <b>9443--595</b>
7. Client Name <input type="checkbox"/> Self <b>PhRMA</b>			6. House ID # <b>316-98054</b>

**TYPE OF REPORT** 8. Year 2002 Midyear (January 1-June 30) ☒ **OR** Year End (July 1-December 31) ☐

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐ >> Termination Date \_\_\_\_\_

11. No Lobbying ☐

## INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
<b>INCOME</b> relating to lobbying activities for this reporting period was: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input checked="" type="checkbox"/> >> \$ <u>\$180,000.00</u> <div style="text-align: right;">Income (nearest \$20,000)</div>	<b>EXPENSES</b> relating to lobbying activities for this reporting period were: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input type="checkbox"/> >> \$ _____ <div style="text-align: right;">Expenses (nearest \$20,000)</div>
Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	<b>14. REPORTING METHOD.</b> Check box to indicate accounting method. See instructions for description of c <input type="checkbox"/> <b>Method A.</b> Reporting amounts using LDA definition <input type="checkbox"/> <b>Method B.</b> Reporting amounts under section 6033 of the Internal Revenue Code <input type="checkbox"/> <b>Method C.</b> Reporting amounts under section 162(c) of the Internal Revenue Code

Signature \_\_\_\_\_ Date 8/13/02



Registrant Name: Clark & WeinstockClient Name: PhRMA

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)16. Specific Lobbying issues  
see attached page

17. House(s) of Congress and Federal agencies contacted  
**Department of Health & Human Services**  
**Executive Office of the President**  
**House of Representatives**  
**Senate**

☐ Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
<b>Bieron, Brian</b>	<b>Policy Director, House Rules Committee</b>
<b>Bonham, Kent</b>	<b>Policy Director for Sen. Chuck Hagel (R-NE)</b>
<b>Fazio, Vic</b>	
<b>Glover Weiss, Juleanna</b>	<b>Press Secretary to the Vice President</b>
<b>Gribbin, Dave</b>	
<b>Kutler, Ed</b>	
<b>Mathews, Jim</b>	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature \_\_\_\_\_

Date 8/13/02



Registrant Name: Clark & WeinstockClient Name: PhRMA

Item	Description	Data
16	Lobbying Issues	<p>Lobbied for Medicare reform and to provide prescription drug coverage for seniors:</p> <p>H.R. 2330, Agriculture, Rural Development, Food and Drug Administration related agencies Appropriations Act 2002</p> <p>H. AMDT. 140, Brown amendment, makes available an additional 2.5 million dollars for the Food and Drug Administration Office of Generic Drugs</p> <p>H. AMDT. 141, Brown amendment, allocates 5 million dollars to carry out the FDA's antibiotic resistance plan</p> <p>H. AMDT. 147, Sanders amendment, amendment sought to prohibit use of funds for enforcement of Section 801 (d) (1) of the Federal Food, Drug and Cosmetic Act</p> <p>H. AMDT. 150, Gutknecht amendment, prohibits use of funds in the bill for purpose of preventing an individual who is not in the business of importing prescription drugs, from importing drugs that (1) appear to be FDA approved, (2) do not appear to be narcotic drugs, and (3) appear to be manufactured, prepared, propagated, compounded, or processed in an establishment pursuant to the Federal Food, Drug and Cosmetic Act</p> <p>H. AMDT. 163, Brown amendment, increases the funding by one million dollars for the responsibilities of the FDA with respect to abbreviated applications for the approval of new drugs</p> <p>H. AMDT. 164, Allen amendment, to prohibit use of funds for approval of new drug applications without disclosure of the cost of research and development of new drug and what portion of that cost is made up with public funding</p> <p>S. 2729, Medicare Prescription Drug Benefit Bill, relating to prescription drug coverage.</p> <p>Intellectual Property and Patent issues including the following:</p> <p>S. 812, Greater Access to Affordable Pharmaceuticals Act of 2001, to amend the federal Food, Drug and Cosmetic Act to provide greater access to affordable pharmaceuticals</p> <p>S. 1229, To amend the Federal Food, Drug, and Cosmetic Act to permit individuals to import prescription drugs in limited circumstances; worked on the Dorgan-Wellstone amendments dealing with intellectual property issues</p>



Registrant Name: **Clark & Weinstock**Client Name: **PhRMA**

Item	Description	Data
18a	Lobbyist Name	Morrison, Timothy
18b	Covered Official Position	Associate Director, Presidential Personnel
18c	New Lobbyist	No
18a	Lobbyist Name	Stach, Deirdre
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Stuart, Sandi
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Urban, Anne
18b	Covered Official Position	Legislative Director, Sen. Robert Kerrey
18c	New Lobbyist	No
18a	Lobbyist Name	Weber, Vin
18b	Covered Official Position	
18c	New Lobbyist	No





Registrant Name: Clark & WeinstockClient Name: PhRMA

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MED (one per page)

16. Specific Lobbying issues  
See attached page.

17. House(s) of Congress and Federal agencies contacted  
Department of Health & Human Services  
Executive Office of the President  
House of Representatives  
Senate

☐ Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bieron, Brian	Policy Director, House Rules Committee
Bonham, Kent	Policy Director for Sen. Chuck Hagel (R-NE)
Fazio, Vic	
Glover Weiss, Juleanna	Press Secretary to the Vice President
Kutler, Ed	
Mathews, Jim	
Morrison, Timothy	Associate Director, Presidential Personnel

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature \_\_\_\_\_

Date 8/13/02



Registrant Name: Clark & WeinstockClient Name: PhRMA

Item	Description	Data
16	Lobbying Issues	<p>Lobbied for Medicare reform and to provide prescription drug coverage for seniors:</p> <p>H.R. 2330, Agriculture, Rural Development, Food and Drug Administration related agencies Appropriations Act 2002</p> <p>H. AMDT. 140, Brown amendment, makes available an additional 2.5 million dollars for the Food and Drug Administration Office of Generic Drugs</p> <p>H. AMDT. 141, Brown amendment, allocates 5 million dollars to carry out the FDA's antibiotic resistance plan</p> <p>H. AMDT. 147, Sanders amendment, amendment sought to prohibit use of funds for enforcement of Section 801 (d) (1) of the Federal Food, Drug and Cosmetic Act</p> <p>H. AMDT. 150, Gutknecht amendment, prohibits use of funds in the bill for purpose of preventing an individual who is not in the business of importing prescription drugs, from importing drugs that (1) appear to be FDA approved, (2) do not appear to be narcotic drugs, and (3) appear to be manufactured, prepared, propagated, compounded, or processed in an establishment pursuant to the Federal Food, Drug and Cosmetic Act</p> <p>H. AMDT. 163, Brown amendment, increases the funding by one million dollars for the responsibilities of the FDA with respect to abbreviated applications for the approval of new drugs</p> <p>H. AMDT. 164, Allen amendment, to prohibit use of funds for approval of new drug applications without disclosure of the cost of research and development of new drug and what portion of that cost is made up with public funding</p> <p>S. 2729, Medicare Prescription Drug Benefit Bill, relating to prescription drug coverage.</p> <p>Intellectual Property and Patent issues including the following:</p> <p>S. 812, Greater Access to Affordable Pharmaceuticals Act of 2001, to amend the federal Food, Drug and Cosmetic Act to provide greater access to affordable pharmaceuticals</p> <p>S. 1229, To amend the Federal Food, Drug, and Cosmetic Act to permit individuals to import prescription drugs in limited circumstances; worked on the Dorgan Wellstone amendments dealing with intellectual property issues</p>



Registrant Name: **Clark & Weinstock**Client Name: **PhRMA**

Item	Description	Data
18a	Lobbyist Name	Stach, Deirdre
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Stuart, Sandi
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Urban, Anne
18b	Covered Official Position	Legislative Director, Sen. Robert Kerrey
18c	New Lobbyist	No
18a	Lobbyist Name	Weber, Vin
18b	Covered Official Position	
18c	New Lobbyist	No



Registrant Name: Clark & WeinstockClient Name: PhRMA

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)16. Specific Lobbying issues  
see attached page17. House(s) of Congress and Federal agencies contacted  
House of Representatives  
Senate☐ Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bieron, Brian	Policy Director, House Rules Committee
Bonham, Kent	Policy Director for Sen. Chuck Hagel (R-NE)
Fazio, Vic	
Glover Weiss, Juleanna	Press Secretary to the Vice President
Gribbin, Dave	
Kutler, Ed	
Mathews, Jim	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if NoneSignature \_\_\_\_\_ Date 8/13/02





Registrant Name: Clark & WeinstockClient Name: PhRMA

Item	Description	Data
16	Lobbying Issues	<p>Lobbied for Medicare reform and to provide prescription drug coverage for seniors:</p> <p>H.R. 2330, Agriculture, Rural Development, Food and Drug Administration related agencies Appropriations Act 2002</p> <p>H. AMDT. 140, Brown amendment, makes available an additional 2.5 million dollars for the Food and Drug Administration Office of Generic Drugs</p> <p>H. AMDT. 141, Brown amendment, allocates 5 million dollars to carry out the FDA's antibiotic resistance plan</p> <p>H. AMDT. 147, Sanders amendment, amendment sought to prohibit use of funds for enforcement of Section 801 (d) (1) of the Federal Food, Drug and Cosmetic Act</p> <p>H. AMDT. 150, Gutknecht amendment, prohibits use of funds in the bill for purpose of preventing an individual who is not in the business of importing prescription drugs, from importing drugs that (1) appear to be FDA approved, (2) do not appear to be narcotic drugs, and (3) appear to be manufactured, prepared, propagated, compounded, or processed in an establishment pursuant to the Federal Food, Drug and Cosmetic Act</p> <p>H. AMDT. 163, Brown amendment, increases the funding by one million dollars for the responsibilities of the FDA with respect to abbreviated applications for the approval of new drugs</p> <p>H. AMDT. 164, Allen amendment, to prohibit use of funds for approval of new drug applications without disclosure of the cost of research and development of new drug and what portion of that cost is made up with public funding</p>



Registrant Name: Clark & WeinstockClient Name: PhRMA

Item	Description	Data
18a	Lobbyist Name	Morrison, Timothy
18b	Covered Official Position	Associate Director, Presidential Personnel
18c	New Lobbyist	No
18a	Lobbyist Name	Stach, Deirdre
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Stuart, Sandi
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Urban, Anne
18b	Covered Official Position	Legislative Director, Sen. Robert Kerrey
18c	New Lobbyist	No
18a	Lobbyist Name	Weber, Vin
18b	Covered Official Position	
18c	New Lobbyist	No



Registrant Name: Clark & WeinstockClient Name: PhRMA**Information Update Page - Complete ONLY where registration information has changed.**

20. Client new address

21. Client new principal place of business (if different from line 20)

City \_\_\_\_\_ State/Zip (or Country) \_\_\_\_\_

22. New general description of client's business or activities

**LOBBYIST UPDATE**23. Name of each previously reported individual who is **no longer** expected to act as a lobbyist for the client  
Urban, Anne**ISSUE UPDATE**24. General lobbying issues previously reported that **no longer** pertain**AFFILIATED ORGANIZATIONS**

25. Add the following affiliated organization(s)

Name	Address	Principal Place of Business (city and state or country)

26. Name of each previously reported organization that is **no longer** affiliated with the registrant or client**FOREIGN ENTITIES**

27. Add the following foreign entities

Name	Address	Principal Place of Business (city and state or country)	Amount of contribution for lobbying activities

28. Name of each previously reported foreign entity that **no longer** owns, or controls, or is affiliated with the registrant, or affiliated organizationSignature \_\_\_\_\_ Date 8/13/02

